key: cord-0996333-okj5p0u9 authors: Weiss, A.; Jellingsoe, M.; Sommer, M. O. A. title: Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review date: 2020-05-23 journal: nan DOI: 10.1101/2020.05.21.20108605 sha: ad7f59d585142444d49adffaea4529c247ea9e6e doc_id: 996333 cord_uid: okj5p0u9 Background The spatial and temporal dynamics of SARS-CoV-2 have been mainly described in form of case series or retrospective studies. In this study, we aimed to provide a coherent overview from published studies of the duration of viral detection and viral load in COVID-19 patients, stratified by specimen type, clinical severity and age. Method We systematically searched PubMed/MEDLINE and Cochrane review database for studies published between 1. November 2019 and 23rd of April 2020. We included studies that reported individual viral data over time measuring negative conversion by two consecutive negative tests, individual clinical severity and age. We excluded studies that reported viral data as patient fraction, reported only baseline data, included solely asymptomatic patients or were interventional studies. Extracted data included author, title, design, sample size, thresholds and genes of RT-PCR, patient age, COVID-19 severity, clinical characteristics, treatment, location of viral sampling, duration of viral detection, and viral load. We pooled the data of selected studies to determine effect estimates of duration of viral detection. Combined viral load was visualized over time. Findings Out of 7226 titles screened, 37 studies met the inclusion criteria and were included in the qualitative analysis and 22 studies in the quantitative analysis comprising 650 COVID-19 patients. The pooled estimate of the duration of positive detection of the virus was in mild adult patients 12.1 days (CI: 10.12, 14.05) after symptom onset in the upper respiratory tract (URT), 24.1 days (CI: 10.02, 38.19) in lower respiratory tract (LRT), and 15.5 days (CI: 8.04, 22.88) in faeces. Further, in mild adult patients, the maximum viral load was ~ 6.61 x 108 viral copies/mL in the URT and ~ 2.69 x 108 viral copies/mL in the LRT, within the first week of symptom onset. The maximum viral load in faeces was reported as ~ 3.55 x 107 copies/mL on Day 9. In moderate-severe adult patients, the pooled estimate of mean duration of positive viral detection in the URT was 15.8 days (CI: 11.12, 20.56) after symptom onset, 23.2 days (CI: 21.49, 24.97) in the LRT, 20.8 days (CI: 16.40, 25.17) in faeces. The maximum viral load was 4.60 x 109 copies/mL on Day 8 in the URT, 3.45 x 108 copies/mL on Day 11 in the LRT, 2.76 x 106 copies/mL on Day 18 in faeces and 1 x 104 copies/mL on Day 3 in blood. In children with mild symptoms, the pooled estimate of the mean duration of positive SARS-CoV-2 viral detection was 11.1 days (CI: 7.14, 15.11) in the URT and 16.0 days (CI: 11.49, 20,47) in the faeces, without reporting quantitative viral data. Viral positivity was detected in the urine and eye in one patient. Interpretation Our analysis showed consistent viral detection from specimen from the URT, the LRT and faeces, irrespective of the clinical severity of COVID-19. Our analysis suggests that SARS-CoV-2 persists for a longer duration in the LRT compared to the URT, whereas the differences in the duration of viral detection between mild and moderate-severe patients is limited in the LRT, but an indication of longer duration of viral detection in feces and the URT for moderate-severe patients was shown. Further, viral load was demonstrated to peak in the URT within first weak of infection, whereas maximum viral load has been observed to occur later and within the second week of infection in the LRT. Funding This study was funded by Innovation Fund Denmark. Background 17 The spatial and temporal dynamics of SARS-CoV-2 have been mainly described in form of case series or 18 retrospective studies. In this study, we aimed to provide a coherent overview from published studies of the 19 duration of viral detection and viral load in COVID-19 patients, stratified by specimen type, clinical severity 20 and age. 21 We systematically searched PubMed/MEDLINE and Cochrane review database for studies published 24 between 1. November 2019 and 23 rd of April 2020. We included studies that reported individual viral data 25 over time measuring negative conversion by two consecutive negative tests, individual clinical severity and 26 age. We excluded studies that reported viral data as patient fraction, reported only baseline data, included 27 solely asymptomatic patients or were interventional studies. Extracted data included author, title, design, 28 sample size, thresholds and genes of RT-PCR, patient age, COVID-19 severity, clinical characteristics, 29 treatment, location of viral sampling, duration of viral detection, and viral load. We pooled the data of 30 selected studies to determine effect estimates of duration of viral detection. Combined viral load was 31 visualized over time. The objective of this paper is to provide a systematic review of the spatial and temporal viral dynamics of 77 SARS-CoV-2 in COVID-19 patients, stratified after clinical severity, location of viral sampling and age, 78 based on individual patient data. The data of the systematic review is then aggregated to report a weighted 79 mean of duration of viral detection, per sampling location for adults and children with mild and moderate-80 severe symptoms. 81 We searched the databases MEDLINE/PUBMED and Cochrane Review with the following search terms: 84 "SARS-CoV-2 [MESH]" OR "COVID 19 [MESH]" alone, or in combination with "virology" OR "viral" 85 Data were extracted from the full text/supplemental material or if only available in graphs digitalized using 94 GetData Graph Digitizer © version 2.26.0.20. We used a pre-defined extraction protocol to capture identical 95 information across studies (incl. author, title, country, design, sample size, thresholds and genes of RT-PCR, 96 frequency of sampling, patient age (median), COVID-19 severity and classification reference, major clinical 97 characteristics, treatment, location of viral sampling, duration of viral detection, viral load). 98 To determine the duration of viral detection from symptom onset, we counted the days from initiation of 100 symptoms (Day 0) to the last positive test (final day was set as Day -1 of first negative test of two consecutive 101 tests for daily sampling). However, in some studies the sampling frequency was not daily, meaning that the 102 last positive test does not equal Day -1 of first negative test. Therefore, we also reported the duration of viral 103 detection until the last positive swab, to not introduce any predictions into the summary measures. In the 104 case that the day of the positive test was not reported for a patient, we excluded this patient in the overall 105 summary measure, as the duration of viral detection becomes predictive. Also, in case a positive test was 106 not reported, we could not be sure that this patient was tested at all positive for the virus at the specific 107 sampling location. Furthermore, for patients that did not clear the virus within the time frame of sampling, 108 we used the day of the last positive test as final day to not introduce bias into the data by excluding these 109 and leaving out patients that needed longer to clear the virus than the average. Finally, we also recorded the 110 duration of viral detection in case recurrence of positivity was observed, meaning a positive test was detected 111 after two negative ones have been obtained. To measure the duration in regard to the "recurrence" endpoint, 112 the final day was also set as Day -1 of the first negative test of two consecutive negative tests. 113 In case clinical severity was not categorized into mild, moderate or severe by the authors of the publication, 114 we conducted this categorization with the symptoms reported, based on definitions described by Wu et 115 al.. 2 Asymptomatic patients were excluded. 116 Statistical analysis comparing the average load per sampling location across each study was performed using 126 unpaired t test, not assuming consistent SD and using a two stage setup false discovery rate approach of 127 We included studies measuring duration positive detection of SARS-CoV-2 in days after symptom onset, 132 but not after hospitalization ensuring that an identical Day 0 is set across studies. Patients equal to 18 years 133 or older were classified as adults (if only median was recorded, the median age was considered for 134 categorization). Single case series were excluded. In total, 22 Studies were included in the aggregation of 135 data. 4-25 136 Oro-/nasopharyngeal throat and nasal swabs were combined to "URT", sputum and tracheal aspirate to 138 "LRT", anal swabs and stool to "faeces", and plasma and serum to "Blood". Mild disease severity was kept 139 as mild and moderate and severe disease severity were merged to moderate-severe in aggregation analysis. 140 Aggregation of study data of duration of viral detection was conducted in ReviewManager 5.3. Standard 142 error was computed according to STDEV/(SQRT(N)). We used generic inverse variance as a data type 143 (mean and SE), and random effect as analysis model. Effect measures were shown as mean with 95% 144 confidence interval (CI). Heterogeneity was measured by I 2 . Forest plots are provided for selected data 145 Role of funding source 147 review. Reasons for exclusion were: individual patient data was missing and/or only median of duration of 157 viral detection was demonstrated, clinical severity or age was not reported or only baseline viral data were 158 Overview of studies describing duration of viral detection in COVID-19 patients 160 The data summary of the selected studies, describing duration of viral detection as days after symptom onset 161 (as mean and SD) is displayed in Table 2 and days after hospitalization in Table 3 . More details of each 162 study, including clinical characteristics can be found in Table S2 in the supplementary material. 163 The SARS-CoV-2 virus is detected in both in the lower and upper respiratory tract, and faeces, irrespective 164 of the severity of the disease. 165 The average duration of positive SARS-CoV-2 viral detection (Day -1) from URT specimens ranged from 166 7.9 days to 20 days after symptom onset in mild adult patients, and from 6 to 30.8 days in moderate-severe 167 patients. The average duration of positive SARS-CoV-2 viral detection from LRT specimens ranged from 168 8 days to 38.4 days after symptom onset in mild adult patients, and from 6 days to 26.9 days in adults with 169 moderate-severe symptoms. In children with mild COVID-19 symptoms, average duration of positive 170 SARS-CoV-2 viral detection ranged from 5.7 days to 17 days after symptom onset in the URT and was 171 reported as 13 days in the LRT in one study 16 Generally, the average duration of viral detection only differed minimally when setting the final day as Day 182 -1 of first negative test (results described in text above) or as day of last positive test in the above patient 183 populations. 184 We aggregated the data of 22 selected studies to report a weighted mean of the duration of positive SARS-186 CoV-2 viral detection. We report the weighted mean for both outcome measures, negative conversion 187 defined by obtaining two consecutive negative samples and negative conversion after recurrence (positive 188 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20108605 doi: medRxiv preprint sample was detected after two consecutive negatives were obtained). As sampling frequency varied and was 189 not daily for all the studies, we also report the results obtained when setting different endpoint measures: 1) 190 final day of positive detection of virus is day -1 of first negative of two consecutive measurement and 2) 191 final day of positive detection of virus is the day on which last positive test was obtained, in case Day -1 192 and last positive day were not identical, to avoid introducing predictions into the outcome measures. 193 Notably, there was a portion of patients that did not reach viral negativity within the time of sampling for 194 which we reported the day of the last positive test as final day. Considering studies that were included in 195 the aggregation analysis, the share of mild patients (children and adults) that did not reach negativity were 196 27/139 for URT specimen, 6/52 for LRT specimen and 26/45 for faecal specimen. Regarding moderate-197 severe patients (children and adults), these were 14/154 for URT specimen, 6/112 for LRT specimen, 0/38 198 for blood specimen and 10/110 for faecal specimen. For the overall patient population, the patients that did 199 not clear within the sampling time accounted for 14% of the whole dataset. 200 We aggregated the data of selected studies to report a weighted mean of duration of positive SARS-CoV-2 201 viral detection in both URT and LRT for mild and moderate-severe patients. We chose to display the results 202 of the aggregated data for which the final day was set as Day -1 of first negative in the main text of this 203 manuscript, as this is the most conservative approach ( estimates for all data groupings, including recurrence, can be found in the Supplementary Table S3 . 206 In total we included data from 650 patients in this analysis. Notably, a high heterogeneity (I 2 ~ 80-90%) was 207 observed in the majority of the subgroup aggregation analysis indicating that these data should be interpreted 208 cautiously and only considered as trends. In children with mild symptoms, the pooled estimate of the mean duration of positive SARS-CoV-2 viral 218 detection after symptom was 11.1 days (CI: 7.14, 15.11) in URT and 16.0 days (CI: 11.49, 20, 47) in the 219 faeces, (Figure 3) . No viral detection was reported in the blood for children. 220 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10. 1101 Generally, the mean duration of positive SARS-CoV-2 viral detection accounting for recurrence of 221 positivity did not differ substantially in mild adults or children (if different, less than 1 Day difference). But, 222 in moderate-severe patients the pooled estimate of the mean duration of positive SARS-CoV-2 viral 223 detection was on average approximately 3.4 days longer for LRT specimen and 1.2 days for faeces, 224 accounting for recurrence of viral positivity. 225 To investigate whether the viral load differs between disease severity and sampling location, we combined 227 data from four published studies and analyzed the viral load per patient as a function of time, stratified after 228 clinical severity (mild and moderate-severe) and location of sampling (URT, LRT and faeces) (Figure 4) . 229 No quantitative viral data was available for children and only one study reported limited quantitative data 230 of blood specimen (four datapoints). 19 231 In mild patients, viral load was highest during the first week in the URT having a maximum viral load of 232 ~ 6.61 x 10 8 viral copies/mL on Day 4, whereas the maximum viral load reported for LRT was ~ 2.69 x 10 8 233 copies/mL on Day 6 ( Table 4 ). The maximum viral load in faeces was reported as ~ 3.55 x 10 7 copies/mL 234 on Day 9 in mild patients. The average viral load was found to be significantly higher in LRT relative to 235 URT in the Woelfel et al. 6 study (t test, q < 0.001) (Figure 4) . However, as this was the only study which 236 allowed this comparison, additional studies of quantitative viral dynamics are needed to assess the viral load 237 of the URT compared to LRT. 238 In moderate-severe patients, the maximum viral load was reported as 4.60 x 10 9 copies/mL on Day 8 in 239 URT and 3.45 x 10 8 copies/mL on Day 11 in LRT. Maximum viral load in faeces was shown to be 2.76 x 240 10 6 copies/mL on Day 18 and 1 x 10 4 copies/mL on Day 3 in blood specimen. No significant difference was 241 found in the average viral load comparing URT and LRT samples in this disease population. 242 In this study we conduct a systematic review of the spatial and temporal viral dynamics of SARS-CoV-2 244 stratified after age and clinical severity. We report the per study data of duration of viral detection and viral 245 load over time, but also show aggregated data of these, providing a better basis for interpretation. While 246 viral trophism likely extends beyond the specimens described in this study 26 , the lack of data on viral load 247 from other locations has limited our analysis to faeces, blood, URT and LRT . 248 Additionally, this study has several limitations which need to be considered. First, different genes and 249 thresholds were used to assess negative conversion of SARS-CoV-2 hampering the direct comparison of 250 studies. Second, the classification of clinical symptoms into the severity categories, mild, moderate, severe 251 was based on different guidelines across the studies and we were not able to unify and verify all (mostly 252 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20108605 doi: medRxiv preprint due to missing individual symptom data). Third, studies that only reported fractions or median of duration 253 of viral shedding were excluded, which might introduce a selection bias into this review. Fourth, the viral 254 load was measured via RT-PCR, which cannot differentiate dead virus particle, and hence data presented 255 here might not necessarily reflect active viral replication. However, this technique is currently used 256 worldwide to measure the quantities of SARS-CoV-2. Fifth, a portion of the patients included in this review 257 (14 %) did not clear the virus in the time frame of sampling, hence the here presented data might be an 258 underestimation of the duration of virus detection. Finally, our aggregation analysis exhibited a high 259 heterogeneity (I 2 ~ 80-90%), which highlights that these data should be interpreted cautiously and only 260 considered as trends. 261 Regardless of these limitations, some trends can be extracted from this analysis. Firstly, we consistently find 262 that SARS-CoV-2 is detected in LRT, URT and fecal specimens, irrespective of clinical severity of disease. 263 Second, our data indicates that the duration of detection of SARS-CoV-2 is longer in LRT than the URT. 264 Third, there seems to be little difference in the duration of detection of SARS-CoV-2 in mild patients as 265 opposed to moderate-severe patients in the LRT, but an indication of longer duration of viral detection in 266 feces and the URT for moderate-severe patients was shown. Fourth, viral load in URT peaks within the first 267 week of infection, whereas viral load in LRT and faeces within the second week of infection. 268 In conclusion, we believe that this systematic review can support refinement of mathematical modelling as 269 well as aid in the definition of appropriate endpoints for clinical trials tested therapeutic intervention aimed 270 at reducing viral load of SARS-CoV-2. Furthermore, it highlights the importance of testing for viral presence 271 in the LRT, which may clear more slowly compared to the URT. 272 273 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020 . . https://doi.org/10.1101 All authors are employed at UNION therapeutics at the time of the conductance of the study. The project has received funding support from Innovation Fund Denmark. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020 . . https://doi.org/10.1101 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020 . . https://doi.org/10.1101 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20108605 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20108605 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20108605 doi: medRxiv preprint Pooled estimate for (A) all mild patients (non-treated and treated) and URT specimens, (B) all moderate-severe patients and URT specimen, (C) all mild patients and LRT specimen, (D) all moderate-severe and LRT specimen, (E) all mild patients and faecal specimen, (F) moderate-severe and faecal specimen and (G) moderatesevere patients and blood specimen. The forest plots include data that describe duration of viral detection defining the final day as day -1 of first negative day of two consecutive negatives. CI: Confidence Interval; D-1: Day -1 of first negative test of two consecutive; FCS: Faeces, LRT: Lower respiratory tract, SE: Standard error, URT: Upper respiratory tract. Temporal dynamic of viral detection in (A) URT specimen in mild patients, (B) LRT specimen in mild patients, (C) fecal specimen in mild patients, (D) URT specimen in moderate-severe patients, (E) LRT specimen in moderate-severe patients, (F) fecal specimen in moderate-severe patients. Four Studies were included 6, 11, 12, 19 . DL: limit of detection. Bar graph displaying mean with SD. **** q < 0.001, unpaired t-test using false discovery approach of Benjamini, Krieger and Yekutieli; M/S : Moderate-severe, URT: upper respiratory tract , LRT: lower respiratory tract. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10. 1101 Characteristics of pediatric SARS-CoV-2 infection and potential evidence 304 for persistent fecal viral shedding SARS-CoV-2-Positive Sputum and Feces After Conversion of Pharyngeal Samples in 306 Patients With COVID-19 SARS-CoV-2-Positive Sputum and Feces After Conversion of Pharyngeal 307 Samples in Patients With COVID-19 The duration of viral shedding of discharged patients with severe COVID-19 Patients of COVID-19 may benefit from sustained lopinavir regimen and the increase of eosinophil may predict the outcome of COVID-19 progression Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19 Digestive Symptoms in COVID-19 Patients with Mild 316 Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes SARS-CoV-2 Viral Load in Clinical Samples of Critically Ill 319 Clinical characteristics of 24 asymptomatic infections with COVID-19 First 12 patients with coronavirus disease 2019 (COVID-19) in the United States